192 related articles for article (PubMed ID: 34193711)
61. [Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
Lai FF; Li J; Ji M; Zhou Q; Wang LY; Chen XG
Yao Xue Xue Bao; 2016 Jun; 51(6):907-12. PubMed ID: 29879343
[TBL] [Abstract][Full Text] [Related]
62. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T
Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898
[TBL] [Abstract][Full Text] [Related]
63. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
[TBL] [Abstract][Full Text] [Related]
64. Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Wang J; Li H; He G; Chu Z; Peng K; Ge Y; Zhu Q; Xu Y
J Med Chem; 2020 Jan; 63(1):122-139. PubMed ID: 31846325
[TBL] [Abstract][Full Text] [Related]
65. Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone.
Kayumov M; Jia L; Pardaev A; Song SS; Mirzaakhmedov S; Ding C; Cheng YJ; Zhang RI; Bao X; Miao ZH; He JX; Zhang A
Eur J Med Chem; 2022 Oct; 240():114574. PubMed ID: 35785724
[TBL] [Abstract][Full Text] [Related]
66. Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors.
Yu J; Gou W; Shang H; Cui Y; Sun X; Luo L; Hou W; Sun T; Li Y
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):952-972. PubMed ID: 35317687
[TBL] [Abstract][Full Text] [Related]
67. Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor.
Liu X; Wei X; Li X; Yu R; Jiang T; Zhao C
Bioorg Med Chem; 2022 Sep; 69():116892. PubMed ID: 35764034
[TBL] [Abstract][Full Text] [Related]
68. Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1.
Hulse M; Caruso LB; Madzo J; Tan Y; Johnson S; Tempera I
PLoS Pathog; 2018 Nov; 14(11):e1007394. PubMed ID: 30395643
[TBL] [Abstract][Full Text] [Related]
69. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
[TBL] [Abstract][Full Text] [Related]
70. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
[TBL] [Abstract][Full Text] [Related]
71. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
Zheng M; Mex M; Götz KH; Marx A
Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829
[TBL] [Abstract][Full Text] [Related]
72. Three-component Castagnoli-Cushman reaction with ammonium acetate delivers 2-unsubstituted isoquinol-1-ones as potent inhibitors of poly(ADP-ribose) polymerase (PARP).
Safrygin A; Zhmurov P; Dar'in D; Silonov S; Kasatkina M; Zonis Y; Gureev M; Krasavin M
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1916-1921. PubMed ID: 34461785
[TBL] [Abstract][Full Text] [Related]
73. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
74. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P
Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465
[TBL] [Abstract][Full Text] [Related]
75. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
[TBL] [Abstract][Full Text] [Related]
76. Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
Bioorg Med Chem Lett; 2021 Jan; 31():127710. PubMed ID: 33246105
[TBL] [Abstract][Full Text] [Related]
77. [
Guibbal F; Hopkins SL; Pacelli A; Isenegger PG; Mosley M; Torres JB; Dias GM; Mahaut D; Hueting R; Gouverneur V; Cornelissen B
Mol Imaging Biol; 2020 Oct; 22(5):1226-1234. PubMed ID: 32342268
[TBL] [Abstract][Full Text] [Related]
78. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
79. Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.
Tang L; Wu W; Zhang C; Shi Z; Chen D; Zhai X; Jiang Y
Bioorg Chem; 2021 Sep; 114():105026. PubMed ID: 34186467
[TBL] [Abstract][Full Text] [Related]
80. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]